Journal of Shanghai Jiao Tong University (Medical Science) >
Progress and controversy in comprehensive treatment of hilar cholangiocarcinoma
Received date: 2021-07-27
Online published: 2022-01-28
Supported by
National Natural Science Foundation of China(81874181)
Hilar cholangiocarcinoma is a tumor with a poor prognosis, which is difficult to diagnosis in the early stage and has caused lots of controversies in clinical treatment. At present, surgical resection provides the main possibility for cure. Precise evaluation and adequate preparation before surgery and safe, effective, standardized resection are the key methods to successful treatment. Comprehensive treatment based on chemotherapy improves the survival of patients. In the future, guided by concepts of oncology, comprehensive treatment of multiple modes, containing surgery, chemotherapy, targeted therapy, immune therapy and biological therapy, is the development trend of hilar cholangiocarcinoma treatment.
Wei CHEN , Yingbin LIU . Progress and controversy in comprehensive treatment of hilar cholangiocarcinoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(1) : 1 -8 . DOI: 10.3969/j.issn.1674-8115.2022.01.001
| 1 | RERKNIMITR R, ANGSUWATCHARAKON P, RATANACHU-EK T, et al. Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma[J]. J Gastroenterol Hepatol, 2013, 28(4): 593-607. |
| 2 | WRONKA K M, GR?T M, STYPU?KOWSKI J, et al. Relevance of preoperative hyperbilirubinemia in patients undergoing hepatobiliary resection for hilar cholangiocarcinoma[J]. J Clin Med, 2019, 8(4). |
| 3 | 顾海涛, 张金彦, 王兆文, 等. 肝门部胆管癌合并梗阻性黄疸患者术前胆道引流疗效分析[J]. 中华肝脏外科手术学电子杂志, 2021, 10(1): 29-32. |
| 4 | 刘颖斌, 王许安. 胆道恶性肿瘤外科治疗的问题和对策[J]. 中华消化外科杂志, 2019, 18(2): 117-122. |
| 5 | 田伏洲, 石力, 汤礼军, 等. 对恶性梗阻性黄疸术前减黄指标的再认识(附28例临床分析)[J]. 中国现代普通外科进展, 2010, 13(1): 1-4. |
| 6 | 程石, 赵修浩. 肝门部胆管癌术前减黄临床意义[J]. 腹部外科, 2019, 32(5): 319-323. |
| 7 | KOMAYA K, EBATA T, YOKOYAMA Y, et al. Verification of the oncologic inferiority of percutaneous biliary drainage to endoscopic drainage: a propensity score matching analysis of resectable perihilar cholangiocarcinoma[J]. Surgery, 2017, 161(2): 394-404. |
| 8 | HIGUCHI R, YAZAWA T, UEMURA S, et al. ENBD is associated with decreased tumor dissemination compared to PTBD in perihilar cholangiocarcinoma[J]. J Gastrointest Surg, 2017, 21(9): 1506-1514. |
| 9 | 王杰, 刘厚宝. 肝门部胆管癌术前胆道引流的现状和研究进展[J]. 中华肝胆外科杂志, 2018, 24(1): 59-64. |
| 10 | COELEN R J S, ROOS E, WIGGERS J K, et al. Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(10): 681-690. |
| 11 | SEWNATH M E, KARSTEN T M, PRINS M H, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice[J]. Ann Surg, 2002, 236(1): 17-27. |
| 12 | 戴朝六, 许永庆. 梗阻性黄疸术前减黄的争议[J]. 肝胆外科杂志, 2011, 19(3): 232-234. |
| 13 | OLTHOF P B, COELEN R J S, WIGGERS J K, et al. High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry[J]. HPB (Oxford), 2017, 19(5): 381-387. |
| 14 | 陈焕伟, 邓斐文, 王峰杰, 等. 肝脏离断联合门静脉结扎两步肝切除术治疗复杂肝门部肿瘤[J]. 中华肝胆外科杂志, 2014, 20(7): 532-535. |
| 15 | 赵帅, 王许安, 刘颖斌. 肝门胆管癌的外科争议及围肝门切除[J]. 肝胆胰外科杂志, 2016, 28(4): 346-350. |
| 16 | HIGUCHI R, YAMAMOTO M. Indications for portal vein embolization in perihilar cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2014, 21(8): 542-549. |
| 17 | NAGINO M, KAMIYA J, NISHIO H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up[J]. Ann Surg, 2006, 243(3): 364-372. |
| 18 | MANSOUR J C, ALOIA T A, CRANE C H, et al. Hilar cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford), 2015, 17(8): 691-699. |
| 19 | YI B, XU A M, LAI E C, et al. Preoperative portal vein embolization for hilar cholangiocarcinoma: a comparative study[J]. Hepatogastroenterology, 2010, 57(104): 1341-1346. |
| 20 | SCHADDE E, ARDILES V, SLANKAMENAC K, et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis[J]. World J Surg, 2014, 38(6): 1510-1519. |
| 21 | SPARRELID E, GILG S, BRISMAR T B, et al. Rescue ALPPS is efficient and safe after failed portal vein occlusion in patients with colorectal liver metastases[J]. Langenbecks Arch Surg, 2017, 402(1): 69-75. |
| 22 | 徐辉, 鲁正. 肝门胆管癌的术前评估策略[J]. 国际外科学杂志, 2013, 40(11): 772-775. |
| 23 | NI Q, WANG H, ZHANG Y, et al. MDCT assessment of resectability in hilar cholangiocarcinoma[J]. Abdom Radiol (NY), 2017, 42(3): 851-860. |
| 24 | 刘颖斌, 吴向嵩. 胆道恶性肿瘤外科治疗的焦点及热点[J]. 肝胆胰外科杂志, 2019, 31(2): 69-71,75. |
| 25 | XIONG J, NUNES Q M, HUANG W, et al. Major hepatectomy in bismuth types Ⅰ and Ⅱ hilar cholangiocarcinoma[J]. J Surg Res, 2015, 194(1): 194-201. |
| 26 | LEE S G, SONG G W, HWANG S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience[J]. J Hepatobiliary Pancreat Sci, 2010, 17(4): 476-489. |
| 27 | 中华医学会外科学分会胆道外科学组, 中国医师协会外科医师分会胆道外科学组. 围肝门区域外科技术临床应用路径中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(6): 626-633. |
| 28 | XIANG S, LAU W Y, CHEN X P. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure[J]. Int J Colorectal Dis, 2015, 30(2): 159-171. |
| 29 | IKEYAMA T, NAGINO M, ODA K, et al. Surgical approach to bismuth type Ⅰ and Ⅱ hilar cholangiocarcinomas: audit of 54 consecutive cases[J]. Ann Surg, 2007, 246(6): 1052-1057. |
| 30 | EBATA T, WATANABE H, AJIOKA Y, et al. Pathological appraisal of lines of resection for bile duct carcinoma[J]. Br J Surg, 2002, 89(10): 1260-1267. |
| 31 | KAWARADA Y, ISAJI S, TAOKA H, et al. S4a + S5 with caudate lobe (S1) resection using the Taj Mahal liver parenchymal resection for carcinoma of the biliary tract[J]. J Gastrointest Surg, 1999, 3(4): 369-373. |
| 32 | WANG S, TIAN F, ZHAO X, et al. A new surgical procedure “dumbbell-form resection” for selected hilar cholangiocarcinomas with severe jaundice: comparison with hemihepatectomy[J]. Medicine (Baltimore), 2016, 95(2): e2456. |
| 33 | 董家鸿, 项灿宏, 石军, 等. 以围肝门切除为本的肝门部胆管癌治愈性切除术的临床疗效[J]. 中华消化外科杂志, 2017, 16(10): 1053-1060. |
| 34 | BAGANTE F, TRAN T, SPOLVERATO G, et al. Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme[J]. J Am Coll Surg, 2016, 222(5): 750-759. |
| 35 | KITAGAWA Y, NAGINO M, KAMIYA J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection[J]. Ann Surg, 2001, 233(3): 385-392. |
| 36 | MIYAZAKI M, OHTSUKA M, MIYAKAWA S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3rd English edition[J]. J Hepatobiliary Pancreat Sci, 2015, 22(3): 181-196. |
| 37 | AMIN M B, EDGE S, GREENE F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual[M]. 8th ed. New York: Springer, 2017. |
| 38 | IGAMI T, NISHIO H, EBATA T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era” the Nagoya University experience[J]. J Hepatobiliary Pancreat Sci, 2010, 17(4): 449-454. |
| 39 | 汤朝晖, 魏妙艳, 唐陈伟, 等. 肝门部胆管癌根治术区域淋巴结清扫范围探讨[J]. 中国普外基础与临床杂志, 2018, 25(7): 775-778. |
| 40 | 张哲栋, 张大方, 谢文勇, 等. 肝门部胆管癌手术切除方式选择和淋巴结清扫的临床应用分析[J]. 中华普通外科杂志, 2019, 34(12): 1017-1020. |
| 41 | HAKEEM A R, MARANGONI G, CHAPMAN S J, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma?[J]. Eur J Gastroenterol Hepatol, 2014, 26(9): 1047-1054. |
| 42 | VALLE J, WASAN H, PALMER D H, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. |
| 43 | MIZUSAWA J, MORIZANE C, OKUSAKA T, et al. Randomized Phase Ⅲ study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)[J]. Jpn J Clin Oncol, 2016, 46(4): 385-388. |
| 44 | HORGAN A M, AMIR E, WALTER T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16): 1934-1940. |
| 45 | MURAKAMI Y, UEMURA K, SUDO T, et al. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma[J]. Ann Surg, 2009, 250(6): 950-956. |
| 46 | 王祥宇, 陆录, 钦伦秀. 肝门部胆管癌临床治疗进展[J]. 中华肝脏外科手术学电子杂志, 2018, 7(4): 253-257. |
| 47 | LAMARCH A, PALMER D H, WASAN H S, et al. ABC-06 A randomised phase Ⅲ, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy[J]. J Clin Oncol, 2019, 37(15 Suppl): 4003. |
| 48 | MONTAL R, SIA D, MONTIRONI C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(2): 315-327. |
| 49 | OTT P A, BANG Y J, PIHA-PAUL S A, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028[J]. J Clin Oncol, 2019, 37(4): 318-327. |
| 50 | MARABELLE A, LE D T, ASCIERTO P A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. |
| 51 | 郭雪冉, 仲飞. 胆管癌免疫治疗的研究进展[J]. 现代肿瘤医学, 2020, 28(11): 1969-1973. |
/
| 〈 |
|
〉 |